Lung Cancer: Targets and Therapy最新文献_第4页

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib. 期待已久的靶向治疗非小细胞肺癌KRAS突变:聚焦阿达格拉西。

IF 3.6

Lung Cancer: Targets and Therapy Pub Date : 2022-11-10 eCollection Date: 2022-01-01 DOI: 10.2147/LCTT.S383662

Danielle Brazel, Zhaohui Arter, Misako Nagasaka

引用次数: 2

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs? 聚焦于Furmonertinib (Alflutinib, AST2818)第三代EGFR TKIs中的瑞士军刀(del19, L858R, T790M，外显子20插入，“不常见的g719x, S768I, L861Q”)?

IF 3.6

Lung Cancer: Targets and Therapy Pub Date : 2022-10-25 eCollection Date: 2022-01-01 DOI: 10.2147/LCTT.S385437

Shannon S Zhang, Sai-Hong Ignatius Ou

{"title":"Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, \"uncommon-G719X, S768I, L861Q\") Among the Third-Generation EGFR TKIs?","authors":"Shannon S Zhang, Sai-Hong Ignatius Ou","doi":"10.2147/LCTT.S385437","DOIUrl":"https://doi.org/10.2147/LCTT.S385437","url":null,"abstract":"Osimertinib, a third-generation (3G) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is now considered the standard of care for the first-line (1L) treatment of advanced EGFR+ NSCLC due to statistically significant improved progression-free survival (PFS) and overall survival (OS) compared with first-generation (1G) treatment from the FLAURA trial. Recently two other 3G EGFR TKIs (aumolertinib and furmonertinib) have been approved in China for treatment of EGFR T790M+ NSCLC. Randomized Phase 3 trials of these two 3G EGFR TKIs have also demonstrated PFS over gefitinib respectively. Among these two Chinese home-grown, 3G EGFR TKIs, furmonertinib seems to most closely resemble osimertinib in terms of dosing regimen, efficacy and adverse events profile. In this article, we reviewed the clinical activity and adverse events of furmonertinib at 80 mg daily (approved dose), potential usage of 160 mg daily for CNS metastasis in EGFR+ NSCLC, and usage of 160 mg or 240 mg daily in EGFR exon20 insertion positive (EGFRex20ins+) NSCLC patients.","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2022-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e0/7d/lctt-13-67.PMC9617553.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40659985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy. SCLC的精氨酸剥夺:机制和治疗前景。

IF 3.6

Lung Cancer: Targets and Therapy Pub Date : 2022-09-05 eCollection Date: 2022-01-01 DOI: 10.2147/LCTT.S335117

Joséphine Carpentier, Iuliia Pavlyk, Uma Mukherjee, Peter E Hall, Peter W Szlosarek

{"title":"Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy.","authors":"Joséphine Carpentier, Iuliia Pavlyk, Uma Mukherjee, Peter E Hall, Peter W Szlosarek","doi":"10.2147/LCTT.S335117","DOIUrl":"https://doi.org/10.2147/LCTT.S335117","url":null,"abstract":"Arginine deprivation has gained increasing traction as a novel and safe antimetabolite strategy for the treatment of several hard-to-treat cancers characterised by a critical dependency on arginine. Small cell lung cancer (SCLC) displays marked arginine auxotrophy due to inactivation of the rate-limiting enzyme argininosuccinate synthetase 1 (ASS1), and as a consequence may be targeted with pegylated arginine deiminase or ADI-PEG20 (pegargiminase) and human recombinant pegylated arginases (rhArgPEG, BCT-100 and pegzilarginase). Although preclinical studies reveal that ASS1-deficient SCLC cell lines are highly sensitive to arginine-degrading enzymes, there is a clear disconnect with the clinic with minimal activity seen to date that may be due in part to patient selection. Recent studies have explored resistance mechanisms to arginine depletion focusing on tumor adaptation, such as ASS1 re-expression and autophagy, stromal cell inputs including macrophage infiltration, and tumor heterogeneity. Here, we explore how arginine deprivation may be combined strategically with novel agents to improve SCLC management by modulating resistance and increasing the efficacy of existing agents. Moreover, recent work has identified an intriguing role for targeting arginine in combination with PD-1/PD-L1 immune checkpoint inhibitors and clinical trials are in progress. Thus, future studies of arginine-depleting agents with chemoimmunotherapy, the current standard of care for SCLC, may lead to enhanced disease control and much needed improvements in long-term survival for patients.","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2022-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/4b/lctt-13-53.PMC9462517.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33466130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. 聚焦特泊替尼和卡马替尼治疗MET 14外显子跳越突变的非小细胞肺癌。

IF 5.1

Lung Cancer: Targets and Therapy Pub Date : 2022-05-13 eCollection Date: 2022-01-01 DOI: 10.2147/LCTT.S360574

Danielle Brazel, Shannon Zhang, Misako Nagasaka

引用次数: 0

ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression? 作为IMpower150诞生的崎崎“冲锋武士”的东方-31,MARIPOSA-2是否会在3g后EGFR TKI进程的“明治近代化”中留下深刻印象?

IF 3.6

Lung Cancer: Targets and Therapy Pub Date : 2022-03-01 DOI: 10.2147/LCTT.S355503

M. Nagasaka, S. Ou

引用次数: 5

An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma 恶性胸膜间皮瘤新出现的治疗方案的最新进展

IF 3.6

Lung Cancer: Targets and Therapy Pub Date : 2022-03-01 DOI: 10.2147/LCTT.S288535

A. Davis, H. Ke, S. Kao, N. Pavlakis

{"title":"An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma","authors":"A. Davis, H. Ke, S. Kao, N. Pavlakis","doi":"10.2147/LCTT.S288535","DOIUrl":"https://doi.org/10.2147/LCTT.S288535","url":null,"abstract":"Abstract The treatment paradigm for malignant pleural mesothelioma (MPM) has changed little in the last 18 years. Radical intent treatment, consisting of surgical resection, radiotherapy and chemotherapy, has been offered to a highly select few; however, there is little randomised evidence to validate this approach. Prior to 2020 chemotherapy with platinum and an anti-folate was the only intervention with randomised evidence to demonstrate improved overall survival (OS) in MPM. No systemic therapy had been demonstrated to improve OS in the second line setting until 2020. The publication of the Checkmate 743 trial in 2021 demonstrated a survival benefit of combination immunotherapy over standard chemotherapy in newly diagnosed patients with MPM. This finding was shortly followed by the CONFIRM trial which demonstrates a modest but significant survival benefit of second line nivolumab versus placebo in patients having previously received standard chemotherapy. The results of these trials, recent biomarker directed therapy and chemotherapy adjuncts are discussed within this review. The integration of immunotherapy for the few patients in whom radical surgical therapy is intended is currently the subject of clinical trials and offers the prospect of improving outcomes in this rare but devastating disease.","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83955144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC. 解构ADAURA。对于早期(IB-IIIA) egfr突变的非小细胞肺癌，目前还不是放弃铂类辅助化疗的时候。

IF 3.6

Lung Cancer: Targets and Therapy Pub Date : 2022-01-01 DOI: 10.2147/LCTT.S346922

Danielle Brazel, Misako Nagasaka

引用次数: 0

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib. 解构ADAURA:是时候放弃IB-IIIA EGFR+ NSCLC的辅助铂基化疗了(除了RB改变?)当采用辅助奥希替尼。

IF 3.6

Lung Cancer: Targets and Therapy Pub Date : 2022-01-01 DOI: 10.2147/LCTT.S358902

Shannon S Zhang, Sai-Hong Ignatius Ou

{"title":"Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib.","authors":"Shannon S Zhang, Sai-Hong Ignatius Ou","doi":"10.2147/LCTT.S358902","DOIUrl":"https://doi.org/10.2147/LCTT.S358902","url":null,"abstract":"Adjuvant cisplatin-based chemotherapy is considered the standard of care for resected stage IB (tumor ≥ 4m)-IIIA non-small cell lung cancer (NSCLC). The ADAURA trial is a randomized placebo-controlled Phase III trial that demonstrated statistically significant improved disease-free survival (DFS) with the use of 3-years of adjuvant osimertinib in resected stage IB-IIIA NSCLC harboring epidermal growth factor receptor (EGFR) del 19 or L858R mutations. Subgroup analysis revealed that the DFS improvement with adjuvant osimertinib is independent of adjuvant chemotherapy in the primary analysis. A recent follow-up report suggested that adjuvant cisplatin-based chemotherapy provided no additional 2-year DFS improvement on top of adjuvant osimertinib regardless of stage (IB, II, or IIIA) and minimal numerical DFS benefit in stage II or IIIA resected EGFR+ NSCLC for those patients who did not receive adjuvant osimertinib. Here, we argue that if clinicians adopt the use of 3 years of adjuvant osimertinib in resected early-stage EGFR+ NSCLC, there is no role for adjuvant platinum-based chemotherapy. The use of adjuvant chemotherapy was balanced between the osimertinib and the placebo arms by stage even though adjuvant chemotherapy was not one of the three stratification factors (del 19 vs L858R; Stage IA vs II vs III; Asians versus non-Asian) in ADAURA. There may be a potential role of adjuvant cisplatin/vinorelbine in a small subgroup of EGFR+ NSCLC patients whose tumor harbors retinoblastoma (RB) gene alterations but requires further investigation.","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/a6/lctt-13-23.PMC9057228.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10615149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers. 全外显子组测序在区分原发性和继发性肺癌中的作用

IF 3.6

Lung Cancer: Targets and Therapy Pub Date : 2021-12-02 eCollection Date: 2021-01-01 DOI: 10.2147/LCTT.S272518

Natalie I Vokes, Jianjun Zhang

{"title":"The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers.","authors":"Natalie I Vokes, Jianjun Zhang","doi":"10.2147/LCTT.S272518","DOIUrl":"10.2147/LCTT.S272518","url":null,"abstract":"Non-small cell lung cancer (NSCLC) that presents with multiple lung tumors (MLTs) poses a challenge to accurate staging and prognosis. MLTs that arise as clonally related secondary metastases from a common primary are higher stage and often require adjuvant chemotherapy or may in fact be incurable stage IV lesions. Conversely, MLTs that represent distinct primaries have a better prognosis and may be overtreated if inappropriately classified as related secondaries. Historically, pathologic and radiographic criteria were used to distinguish between primary and secondary MLTs; however, the advent of genomic profiling has demonstrated limitations to these historic classification systems. In this review, we discuss the use of molecular profiling to distinguish between primary and secondary lung cancers, with a focus on the insights gleaned from whole exome sequencing (WES) analyses. While WES is not yet feasible in routine clinical practice, WES studies have helped elucidate the clonal relationship between primary and secondary lung cancers and provide important context for the application of targeted sequencing panel-based analyses.","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2021-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/0d/lctt-12-139.PMC8648100.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39793525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer. 聚焦 Amivantamab（JNJ-61186372）治疗表皮生长因子受体外显子 20 插入阳性非小细胞肺癌。

IF 5.1

Lung Cancer: Targets and Therapy Pub Date : 2021-12-02 eCollection Date: 2021-01-01 DOI: 10.2147/LCTT.S337861

Danielle Brazel, Misako Nagasaka

引用次数: 0